WALTHAM, Mass., Aug. 29, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that company management will discuss AMAG's business and financial outlook, strategy and growth prospects at investor conferences taking place in September 2014.
On Wednesday, September 3, 2014, the company will participate in the Baird 2014 Healthcare Conference and the FBR Inaugural Healthcare Conference:
-
William Heiden, AMAG's chief executive officer, will present at the Baird 2014 Healthcare Conference at 7:55 a.m. ET in New York. A live webcast of the presentation will be accessible through the Investors section of the company's website at www.amagpharma.com, and the webcast will be archived there for 30 days.
- Frank Thomas, AMAG's chief operating officer, will conduct a series of one-on-one meetings with investors at the FBR Inaugural Healthcare Conference in Boston.
In addition, on Monday, September 8, 2014, Mr. Heiden will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference at 2:50 p.m. ET in New York. A live audio webcast of the discussion will be accessible through the Investors section of the company's website at www.amagpharma.com, and the webcast will be archived there for 30 days.
About AMAG
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in the United States. Along with driving continued growth of its products, AMAG intends to continue to expand its portfolio through the in-license or purchase of additional pharmaceutical products or companies, including revenue-generating commercial products and late-stage development assets that leverage its corporate infrastructure and commercial expertise. Our primary goal is to bring to market therapies that provide clear benefits and improve patients' lives. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG Pharmaceuticals, Inc. MuGard is a registered trademark of Access Pharmaceuticals, Inc.